AKBA
Akebia Therapeutics, Inc.
Biotechnology
Market Cap$393M
5Y Perf.-87.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AKBA vs FOLD vs RARE vs KRYS
Revenue, margins, valuation, and 5-year total return — side by side.
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.47B
5Y Perf.+15.9%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-62.1%
KRYS
Krystal Biotech, Inc.
Biotechnology
Market Cap$8.52B
5Y Perf.+461.9%
AKBA vs FOLD vs RARE vs KRYS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AKBA | FOLD | RARE | KRYS |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $393M | $4.47B | $2.55B | $8.52B |
| Revenue (TTM) | $236M | $599M | $669M | $417M |
| Net Income (TTM) | $-5M | $-14M | $-609M | $225M |
| Gross Margin | 83.3% | 89.5% | 83.6% | 92.8% |
| Operating Margin | 9.9% | 5.5% | -83.9% | 42.8% |
| Forward P/E | — | 40.6x | — | 38.3x |
| Total Debt | $0.00 | $444M | $1.28B | $9M |
| Cash & Equiv. | $185M | $214M | $434M | $496M |
AKBA vs FOLD vs RARE vs KRYS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AKBA
FOLD
RARE
KRYS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Akebia Therapeutics… (AKBA) | 100 | 12.7 | -87.3% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 37.9 | -62.1% |
| Krystal Biotech, In… (KRYS) | 100 | 561.9 | +461.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKBA vs FOLD vs RARE vs KRYS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KRYS leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Amicus Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. AKBA also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
AKBA
Akebia Therapeutics, Inc.
The Growth Play
AKBA is the clearest fit if your priority is growth exposure.
- Rev growth 47.5%, EPS growth 93.9%, 3Y rev CAGR -6.9%
- 47.5% revenue growth vs RARE's 20.1%
Best for: growth exposure
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 0.63
- Beta 0.63, current ratio 3.39x
- Beta 0.63 vs RARE's 1.42
- +134.1% vs AKBA's -36.2%
Best for: income & stability and defensive
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
KRYS
Krystal Biotech, Inc.
The Long-Run Compounder
KRYS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 26.2% 10Y total return vs FOLD's 125.0%
- Lower volatility, beta 1.12, Low D/E 0.8%, current ratio 9.95x
- Better valuation composite
- 53.9% margin vs RARE's -91.0%
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AKBA | 47.5% revenue growth vs RARE's 20.1% |
| Value | KRYS | Better valuation composite |
| Quality / Margins | KRYS | 53.9% margin vs RARE's -91.0% |
| Stability / Safety | FOLD | Beta 0.63 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +134.1% vs AKBA's -36.2% |
| Efficiency (ROA) | KRYS | 17.6% ROA vs RARE's -45.8%, ROIC 18.0% vs -89.4% |
AKBA vs FOLD vs RARE vs KRYS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
Segment breakdown not available.
AKBA vs FOLD vs RARE vs KRYS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKRYSLAGGINGRARE
Who Leads Where
KRYS leads in 3 of 6 categories
AKBA leads 1 • FOLD leads 1 • RARE leads 0
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
FOLDAmicus Therapeutics, …
1leads
AKBAAkebia Therapeutics, …
1leads
KRYSKrystal Biotech, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs AKBAvs FOLDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KRYS5/6
Valuation MetricsMultiples, price ratios, and targets
AKBA3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KRYS7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
KRYS5/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KRYS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 2.8x AKBA's $236M. KRYS is the more profitable business, keeping 53.9% of every revenue dollar as net income compared to RARE's -91.0%. On growth, KRYS holds the edge at +31.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AKBAAkebia Therapeuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | KRYSKrystal Biotech, … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $236M | $599M | $669M | $417M |
| EBITDAEarnings before interest/tax | $24M | $40M | -$536M | $185M |
| Net IncomeAfter-tax profit | -$5M | -$14M | -$609M | $225M |
| Free Cash FlowCash after capex | $68M | $10M | -$487M | $237M |
| Gross MarginGross profit ÷ Revenue | +83.3% | +89.5% | +83.6% | +92.8% |
| Operating MarginEBIT ÷ Revenue | +9.9% | +5.5% | -83.9% | +42.8% |
| Net MarginNet income ÷ Revenue | -2.3% | -2.3% | -91.0% | +53.9% |
| FCF MarginFCF ÷ Revenue | +28.6% | +1.6% | -72.8% | +56.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +23.9% | +19.5% | -2.4% | +31.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +51.8% | +3.8% | -17.2% | +52.5% |
KRYS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
AKBA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AKBA's 8.9x EV/EBITDA is more attractive than FOLD's 140.6x.
| Metric | AKBAAkebia Therapeuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | KRYSKrystal Biotech, … |
|---|---|---|---|---|
| Market CapShares × price | $393M | $4.5B | $2.5B | $8.5B |
| Enterprise ValueMkt cap + debt − cash | $208M | $4.7B | $3.4B | $8.0B |
| Trailing P/EPrice ÷ TTM EPS | -74.00x | -80.50x | -4.45x | 42.24x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 40.62x | — | 38.29x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 8.85x | 140.62x | — | 47.84x |
| Price / SalesMarket cap ÷ Revenue | 1.66x | 8.46x | 3.79x | 21.89x |
| Price / BookPrice ÷ Book value/share | 11.67x | 22.73x | — | 7.09x |
| Price / FCFMarket cap ÷ FCF | 5.78x | — | — | 45.08x |
AKBA leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
KRYS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
KRYS delivers a 19.3% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-6 for RARE. KRYS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 2.29x. On the Piotroski fundamental quality scale (0–9), FOLD scores 5/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | AKBAAkebia Therapeuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | KRYSKrystal Biotech, … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -16.4% | -6.1% | -6.1% | +19.3% |
| ROA (TTM)Return on assets | -1.4% | -1.6% | -45.8% | +17.6% |
| ROICReturn on invested capital | — | +4.8% | -89.4% | +18.0% |
| ROCEReturn on capital employed | +13.3% | +4.0% | -46.4% | +14.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 2.29x | — | 0.01x |
| Net DebtTotal debt minus cash | -$185M | $230M | $842M | -$487M |
| Cash & Equiv.Liquid assets | $185M | $214M | $434M | $496M |
| Total DebtShort + long-term debt | $0 | $444M | $1.3B | $9M |
| Interest CoverageEBIT ÷ Interest expense | 1.39x | 1.11x | -14.49x | — |
KRYS leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
KRYS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KRYS five years ago would be worth $41,030 today (with dividends reinvested), compared to $2,241 for RARE. Over the past 12 months, FOLD leads with a +134.1% total return vs AKBA's -36.2%. The 3-year compound annual growth rate (CAGR) favors KRYS at 48.8% vs RARE's -18.0% — a key indicator of consistent wealth creation.
| Metric | AKBAAkebia Therapeuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | KRYSKrystal Biotech, … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.5% | +1.5% | +9.9% | +17.0% |
| 1-Year ReturnPast 12 months | -36.2% | +134.1% | -26.0% | +107.1% |
| 3-Year ReturnCumulative with dividends | +39.6% | +19.0% | -44.9% | +229.6% |
| 5-Year ReturnCumulative with dividends | -50.8% | +50.9% | -77.6% | +310.3% |
| 10-Year ReturnCumulative with dividends | -82.3% | +125.0% | -58.9% | +2615.2% |
| CAGR (3Y)Annualised 3-year return | +11.8% | +6.0% | -18.0% | +48.8% |
KRYS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs AKBA's 36.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AKBAAkebia Therapeuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | KRYSKrystal Biotech, … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 0.63x | 1.42x | 1.12x |
| 52-Week HighHighest price in past year | $4.08 | $14.50 | $42.37 | $303.00 |
| 52-Week LowLowest price in past year | $1.14 | $5.51 | $18.29 | $122.80 |
| % of 52W HighCurrent price vs 52-week peak | +36.3% | +99.9% | +61.2% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 72.2 | 61.0 | 62.0 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 3.0M | 1.8M | 256K |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AKBA as "Buy", FOLD as "Buy", RARE as "Buy", KRYS as "Buy". Consensus price targets imply 170.3% upside for AKBA (target: $4) vs 0.1% for FOLD (target: $15).
| Metric | AKBAAkebia Therapeuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | KRYSKrystal Biotech, … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $14.50 | $51.50 | $332.75 |
| # AnalystsCovering analysts | 11 | 24 | 33 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KRYS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AKBA leads in 1 (Valuation Metrics).
Best OverallKrystal Biotech, Inc. (KRYS)Leads 3 of 6 categories
Loading custom metrics...
AKBA vs FOLD vs RARE vs KRYS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AKBA or FOLD or RARE or KRYS a better buy right now?
For growth investors, Akebia Therapeutics, Inc.
(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Krystal Biotech, Inc. (KRYS) offers the better valuation at 42. 2x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AKBA or FOLD or RARE or KRYS?
On forward P/E, Krystal Biotech, Inc.
is actually cheaper at 38. 3x.
03Which is the better long-term investment — AKBA or FOLD or RARE or KRYS?
Over the past 5 years, Krystal Biotech, Inc.
(KRYS) delivered a total return of +310. 3%, compared to -77. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: KRYS returned +26. 2% versus AKBA's -82. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AKBA or FOLD or RARE or KRYS?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 125% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AKBA or FOLD or RARE or KRYS?
By revenue growth (latest reported year), Akebia Therapeutics, Inc.
(AKBA) is pulling ahead at 47. 5% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AKBA or FOLD or RARE or KRYS?
Krystal Biotech, Inc.
(KRYS) is the more profitable company, earning 52. 6% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AKBA or FOLD or RARE or KRYS more undervalued right now?
On forward earnings alone, Krystal Biotech, Inc.
(KRYS) trades at 38. 3x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 2. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 170. 3% to $4. 00.
08Which pays a better dividend — AKBA or FOLD or RARE or KRYS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AKBA or FOLD or RARE or KRYS better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +125. 0% 10Y return). Both have compounded well over 10 years (FOLD: +125. 0%, RARE: -58. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AKBA and FOLD and RARE and KRYS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AKBA: 23.9% · FOLD: 19.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.